Whilst the results of cardiovascular outcome studies are awaited [2], the GLP‐1/GIP RA tirzepatide has been shown to significantly improve surrogate markers of cardiovascular disease in people with and without diabetes mellitus [33]. This evidence concerns the gene GIP and diabetes mellitus.